An Israeli-developed, thimble-like device worn over a person's index finger
has been proven by clinical studies to predict who is at high risk of
developing endothelial dysfunction - a key precursor of atherosclerosis, a
major component in cardiovascular disease.
Called the Endo-PAT, the device is based on PAT technology that measures
subtle but significant vaso-motion changes through the pneumatic probe on
the finger. It is the only non-invasive device approved by the US Food and
Drug Administration that reliably detects impairment of the endothelial
layer (the inner lining of blood vessels).
Endo-PAT2000 is a simple and easy to use device for assessing endothelial
function. The PAT signal is recorded using Itamar Medical's non-invasive,
pneumatic finger probe. The data recorded is analyzed automatically using
proprietary advanced
Digital Signal Processing algorithms and reports are available within
seconds of completing the test.
Developed and manufactured by Itamar Medical in Cesearea, the screening
technology adds an important dimension to cardiac medicine by allowing
physicians to reliably and non-invasively measure endothelial function and
identify pathological cases of dysfunction, according to foreign
researchers.
Desalination company IDE set for LSE
IDE did not disclose the price range for the proposed offering, but sources
believe that it plans to raise up to $200 million at a company value of $500
million, before money.
IDE was founded in 1965. The company develops both thermal and seawater
reverse osmosis desalination - the two prevailing technologies for seawater
desalination, and is active in 40 countries, including China, India, Israel,
Australia, Latin America, and the US. It has designed and built more than
370 facilities to date. It added that it has an 11% market share in "those
countries where Israeli companies are able to conduct business and compete
on even terms with other businesses.
IDE said that it posted $70.7 million revenue in 2006 and a gross profit of
$26.5 million on $75.6 million in January-September 2007. It added that it
would use proceeds from the IPO for specific projects including investment
in the Hadera desalination facility, and anticipated mergers and
acquisitions.
IDE (IHTIR May 2007) will issue Global Depository Shares (GDS). The issue
is due to take place in December. Goldman Sachs International and Merrill
Lynch International are the global coordinators, bookrunners and
underwriters, and HSBC is the co-lead manager.